Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters.

Publication ,  Journal Article
Hadiprodjo, D; Ryan, T; Truong, M-T; Mercier, G; Subramaniam, RM
Published in: AJR Am J Roentgenol
February 2012

OBJECTIVE: The purpose of this article is to establish (18)F-FDG metabolic imaging parameters to differentiate benign and malignant tumors of the parotid gland. MATERIALS AND METHODS: Forty-nine patients with increased FDG uptake in the parotid gland were selected for the study group (29 men and 20 women; mean age, 63.14 ± 12.32 years). Another 49 patients without head and neck malignancies were selected as the control group (24 men and 25 women; mean age, 65.80 ± 11.51 years); they did not have a parotid lesion or increased FDG uptake in the parotid gland. Maximum standardized uptake value (SUV(max)) was obtained for all patients. Metabolic tumor volume and total glycolytic activity were measured in patients with a discrete parotid lesion (n = 24). Nonparameteric Student t test (Mann-Whitney U test) was performed for between-group analysis. RESULTS: The median SUV(max) of the increased diffuse uptake (2.55; interquartile range [IQR], 1.03-4.07) was significantly lower than the median SUV(max) of tumors (8.48; IQR, 1.46-15.5) (p < 0.01). The median SUV(max) of malignant tumors (11.8; IQR, 4.45-19.15) was significantly (p < 0.05) higher than that of benign tumors (6.4; IQR, 3.4-9.0). There was significant difference (p = 0.003) in the median metabolic tumor volume for malignant tumors (8.9; IQR, 5.1-25.5) and benign tumors or lesions (1.4; IQR, 1.00-2.9). Similar results were found for total glycolytic activity for malignant tumors (67.9; IQR, 24.2-137.6) and benign tumors or lesions (8.4; IQR, 3.9-13.6) (p = 0.002). CONCLUSION: FDG PET/CT SUV(max), metabolic tumor volume, and total glycolytic activity are imaging parameters to differentiate benign and malignant tumors of the parotid gland.

Duke Scholars

Published In

AJR Am J Roentgenol

DOI

EISSN

1546-3141

Publication Date

February 2012

Volume

198

Issue

2

Start / End Page

W185 / W190

Location

United States

Related Subject Headings

  • Triiodobenzoic Acids
  • Tomography, X-Ray Computed
  • Statistics, Nonparametric
  • Retrospective Studies
  • Radiopharmaceuticals
  • Prospective Studies
  • Positron-Emission Tomography
  • Parotid Neoplasms
  • Nuclear Medicine & Medical Imaging
  • Multimodal Imaging
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hadiprodjo, D., Ryan, T., Truong, M.-T., Mercier, G., & Subramaniam, R. M. (2012). Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters. AJR Am J Roentgenol, 198(2), W185–W190. https://doi.org/10.2214/AJR.11.7172
Hadiprodjo, David, Timothy Ryan, Minh-Tam Truong, Gustavo Mercier, and Rathan M. Subramaniam. “Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters.AJR Am J Roentgenol 198, no. 2 (February 2012): W185–90. https://doi.org/10.2214/AJR.11.7172.
Hadiprodjo D, Ryan T, Truong M-T, Mercier G, Subramaniam RM. Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters. AJR Am J Roentgenol. 2012 Feb;198(2):W185–90.
Hadiprodjo, David, et al. “Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters.AJR Am J Roentgenol, vol. 198, no. 2, Feb. 2012, pp. W185–90. Pubmed, doi:10.2214/AJR.11.7172.
Hadiprodjo D, Ryan T, Truong M-T, Mercier G, Subramaniam RM. Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters. AJR Am J Roentgenol. 2012 Feb;198(2):W185–W190.

Published In

AJR Am J Roentgenol

DOI

EISSN

1546-3141

Publication Date

February 2012

Volume

198

Issue

2

Start / End Page

W185 / W190

Location

United States

Related Subject Headings

  • Triiodobenzoic Acids
  • Tomography, X-Ray Computed
  • Statistics, Nonparametric
  • Retrospective Studies
  • Radiopharmaceuticals
  • Prospective Studies
  • Positron-Emission Tomography
  • Parotid Neoplasms
  • Nuclear Medicine & Medical Imaging
  • Multimodal Imaging